Leading healthcare products maker
) recently announced a new software application for its ForceTriad
energy platform. The bipolar resection software application has
been introduced in North America. The ForceTriad tissue fusing and
electrosurgery system is a product from the company's Medical
segment's Energy devices.
The latest software offers better multi-use capabilities to the
ForceTriad platform, which enables the platform to be applied to
additional surgical procedures. It is also adaptable with bipolar
resectoscopes developed by Karl Storz Endoskope and Richard Wolf
Medical Instruments Corporation. Covidien's Valleylab Exchange
software update system can be used to update the ForceTriad. The
software can be deployed to more than 10,000 installed ForceTriad
devices in the U.S.
Along with the TissueFect sensing technology available with
ForceTriad, the new application will enable doctors to perform
transurethral resections of the prostrate. The technically advanced
software application reaffirms Covidien's cost saving strategy as
well as its efforts to enhance healthcare facilities with improved
Covidien is a leading global health care products company with a
rich history of developing high-quality products in a
cost-effective manner. It competes with
Johnson & Johnson
), among others. The company plans to bolster its sales with the
help of strategic acquisitions.
Covidien remains committed to rolling out new products and
technologies, focusing on emerging markets and boosting market
share in core segments through investments in its sales and
marketing infrastructure. It has launched 100 new products over the
last five years and is on track to introduce another 50 products
over the next two years.
However, sustained pricing/procedure volume pressure represents
a headwind. We are currently Neutral on the stock, which carries a
short-term Zacks #3 Rank (Hold).
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
To read this article on Zacks.com click here.